Public Release of Clinical Information - Draft Guidance Document
Guidance documents are meant to provide assistance to industry and health care professionals on how to comply with governing statutes and regulations. Guidance documents also provide assistance to staff on how Health Canada mandates and objectives should be implemented in a manner that is fair, consistent and effective.
Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document may be acceptable provided they are supported by adequate justification. Alternate approaches should be discussed in advance with the relevant program area to avoid the possible finding that applicable statutory or regulatory requirements have not been met.
As a corollary to the above, it is equally important to note that Health Canada reserves the right to request information or material, or define conditions not specifically described in this document, in order to allow the Department to adequately assess the safety, efficacy or quality of a therapeutic product. Health Canada is committed to ensuring that such requests are justifiable and that decisions are clearly documented.
Health Canada invites comments on this draft Guidance document until June 25, 2018. When preparing your comments, please indicate the relevant section(s) and line numbers (in PDF version) to which your comments relate. Comments can be sent by email to: firstname.lastname@example.org.
Table of Contents
- 1. Introduction
- 2. Scope and application
- 2.1 International alignment
- 2.2 Clinical information available to the public
- 2.3 Consideration regarding interim analyses
- 2.4 Individual patient records (individual patient listings and case report forms)
- 2.5 Implementation schedule for the proactive disclosure of clinical information in drug submissions and medical device applications
- 2.6 On-request publication of clinical information found in past drug submissions and medical device applications
- 3. Procedures
- 3.1 Health Canada initiation of the publication of clinical information
- Positive regulatory decisions
- Negative regulatory decisions
- How to request clinical information from past submissions
- Prioritization of requests
- 3.2 Submission of annotated documents with proposed CBI redaction(s) and anonymization
- Relying on previously-redacted information
- 3.3 Health Canada review of annotated documents
- 3.4 Finalization of redacted documents
- 3.5 Publication of final redacted documents
- 4. Requirements for the redaction of Confidential Business Information
- 5. Anonymization of personal information
- 5.1 Principles of protecting personal information
- 5.2 Anonymization process:
- Step 1: Classify the variables
- Step 2: Measure the data risk
- Measurement of data risk for directly-identifying variables
- Measurement of data risk for indirectly-identifying variables
- Reference population
- Risk threshold
- Step 3: De-identify the data
- Data utility
- De-identification of directly-identifying variables
- De-identification of indirectly-identifying variables
- Documenting the anonymization process and governance
- Appendix A: Structure and content of ICH CTD/eCTD M2.5, M2.7 and M5
- Appendix B: Structure and Content of ICH CTD/eCTD Module 5.3 Clinical Study Reports
- Appendix C: Structure and content of Section 4 of IMDRF ToC medical device application
- Appendix D: Process flow chart
- Appendix E: Document naming convention for submissions through the CESG
- Appendix F: Proposed redaction control sheet
- Appendix G: Anonymisation report template
- Appendix H: Certification letter with table of previously redacted information
- Appendix I: Terms and conditions of use
This draft guidance is being published in advance of the coming into force of the proposed regulations that will govern the Public Release of Clinical Information initiative. Consequently, this draft version is based on the proposed regulations published in Canada Gazette I on December 9, 2017 . Revisions, if required, will be published after Canada Gazette II.
Providing public access to clinical information on the safety and efficacy of drugs and on the safety and effectiveness of medical devices can enable independent re-analyses of data, foster new research questions, and benefit Canadians by helping them make informed decisions about their health.
This document is designed to help the public, industry, healthcare professionals and other stakeholders better understand the implementation of Health Canada’s Public Release of Clinical Information initiative, including: the procedures to prepare information for release; the categories of information that continue to be subject to the definition of confidential business information (CBI) and that may be eligible for redaction; and how Health Canada will protect personal information.
This document does not apply to the CBI disclosure authority under section 21.1(3)(c) of the Food and Drugs Act, which permits Health Canada to disclose CBI to certain persons for the purpose of protection or promotion of human health or the safety of the public. Information on this authority can be found in Guidance Document – Disclosure of Confidential Business Information under Paragraph 21.1(3)(c) of the Food and Drugs Act.
1.1 About this guidance document
Guidance documents are meant to assist individuals and organizations to comply with Health Canada's policies and its governing statutes and regulations. They also serve to assist Health Canada staff to implement its mandates in a fair, consistent and effective manner.
Guidance documents are administrative instruments. They do not have force of law and as such they allow for flexibility. Alternate approaches to the implementation of the principles, considerations and requirements described in this document may be acceptable provided they comply with relevant laws. Discussion with the relevant program area in advance is encouraged to determine whether an alternative approach meets applicable statutory or regulatory requirements.
1.2 Terminology and definitions
Food and Drugs Act
Food and Drug Regulations
Medical Device Regulations
Confidential Business Information, as per the meaning in section 2 of the Food and Drugs Act
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Common Technical Document submission format of ICH
Electronic Common Technical Document submission format of ICH
International Medical Device Regulators Forum Table of Contents
Submissions to switch an authorized medical ingredient to non-prescription status.
Has the same meaning as in the Medical Device Regulations:
For information on the classification of medical devices, please refer to Guidance Document: Guidance for the Risk-based Classification System for In Vitro Diagnostic Devices (IVDDs) and Guidance Document - Guidance on the Risk-based Classification System for Non-In Vitro Diagnostic Devices (non-IVDDs).
Means information about an identifiable individual that is recorded in any form as defined in section 3 of the Privacy Act.
Means an investigation in respect of a drug for use in humans that involves human subjects and that is intended to discover or verify the clinical, pharmacological or pharmacodynamic effects of the drug, identify any adverse events in respect of the drug, study the absorption, distribution, metabolism and excretion of the drug, or ascertain the safety or efficacy of the drug. (Food and Drug Regulations C.05.001)
Means information in respect of a clinical trial, as per the meaning in C.08.009.1 (1) of the FDR, or information in respect of clinical studies or investigational testing, as per the meaning in s43.11 of the MDR. For greater clarity, this includes the clinical overviews, clinical summaries, and clinical study reports for drugs, and the summaries and detailed information of all clinical studies and investigational testing that provided evidence of safety and effectiveness for medical devices.
Means the information will not be used to support a marketing authorisation application anywhere in the world, or sold or traded to another person.
Means the current owner of a drug identification number or person or business holding the medical device licence.
Means uniquely-identifying information that is replicable, distinguishable and knowable, and with limited exceptions is not analytically useful.
Means identifying information that can identify an individual through a combination of indirect identifiers, and is analytically useful.
Means the process through which personal information (both direct and indirect identifiers) are rendered de-identified: the information is irrevocably stripped of direct identifiers; a code is not kept to allow future re-linkage; and risk of re-identification of individuals from remaining indirect identifiers is equal to or below the threshold of 0.09.
Means a technique of anonymization that suppresses personal information by placing an opaque box over text or image.
Means a technique of anonymization that uses re-categorization within a range for the purpose of enlarging the number of “like” individuals.
Means a technique applied following generalization that converts a general data range to a specific data point within the original generalized range.
Means a technique of anonymization that applies a random small change to variables to reduce the ability of the data to identify a person.
Means a technique of anonymization that replaces numerical data through the addition or subtraction of a fixed quantity.
Means a technique of anonymization whereby personal information (e.g. subject identification number) is re-coded for the purpose of disassociating the variable from the patient.
Means the group of individuals used to determine the risk of re-identification.
1.3 Policy objective
Health Canada’s objective is to make specified de-identified clinical information in drug submissions and medical device applications publicly available for non-commercial purposes while adhering to Canada’s Privacy Act, its associated regulations and governance, following the completion of Health Canada’s regulatory review process.
2. Scope and application
Health Canada will endeavor to publish de-identified clinical information on a proactive basis, as well as on request for past submissions, as detailed in this guidance. Health Canada receives this clinical information to evaluate the safety and efficacy of drugs (including new drugs and generic drugs) and the safety and effectiveness of medical devices.
For drugs, clinical information is submitted under Division 8 of the FDR in the internationally-harmonized electronic Common Technical Document (eCTD) structure. This includes clinical overviews, summaries within module 2, and clinical study reports within module 5.
For class III and IV medical devices, clinical information is currently received under section 32 (3), and (4) of the MDR. However, Health Canada will soon be adopting an internationally-harmonized structured format for medical device application, known as IMDRF ToC; clinical information will be located within chapter 4 of these applications. Class I and II medical device applications and amendments are out of scope as manufacturers are not required to provide the supporting clinical information that falls within the policy objective.
Chemistry, manufacturing, and other non-clinical information (regardless of location within a drug submission or medical device application) will remain subject to the FDA definition of confidential business information.
Paragraph C.08.009.2 of the FDR describes the circumstances when clinical information within drug submissions ceases to be CBI. These are:
- the issuance of a notice of compliance,
- the issuance of a notice of non-compliance-withdrawal, or
- the issuance of a notice of deficiency-withdrawal.
Similarly, section 43.12 (1) of the MDR describes the circumstances when clinical information within medical device applications that is CBI ceases to be CBI. These are:
- the issuance of a medical device license,
- the issuance of a medical device license amendment, or
- the issuance of a refusal letter.
Paragraph C.08.009.3 of the FDR and section 43.13 of the MDR provide the Minister with the authority to disclose, without notification or consent, clinical information once it has ceased to be CBI under the above circumstances.
This Guidance describes the categories of clinical information Health Canada will disclose proactively, the process for requesting information from past submissions, and the process through which Health Canada will protect personal information and information that continues to be CBI.
2.1 International alignment
Health Canada recognizes the importance of international alignment in clinical data sharing, particularly regarding the release of clinical data that is available in other jurisdictions. Its implementation of the public release of clinical information will seek to align with international best practices, where these conform with Canadian legal requirements and help to advance Canadian policy objectives. Collaboration with the clinical data publication programs of our regulatory partners will help to reduce administrative burden and ensure that personal information is consistently protected.
2.2 Clinical information available to the public
Health Canada will publicly release, following completion of the regulatory process, clinical information regarding the safety and efficacy of drugs in humans and the safety and effectiveness of medical devices.
For drug information provided to Health Canada using the international standard submission format, clinical information is contained in eCTD modules 2.5 (clinical summaries), 2.7 (clinical overviews) and 5.3 (clinical study reports), see appendix A for greater detail. In addition, the released information will include the following appendices to clinical study reports: 16.1.1 (protocol and protocol amendments), 16.1.2 (sample case report forms) and 16.1.9 (statistical analysis plan), see appendix B for greater detail.
Medical device information will be made available to the public at the beginning of the third stage of implementation. Health Canada intends to align publication of medical device information with the adoption of the IMDRF-ToC medical device application format. For medical device information provided to Health Canada in the IMDRF-ToC format, clinical information is contained in chapter 4 and includes the summaries, reports, and evidence, see appendix C for greater detail.
2.3 Consideration regarding interim analyses
An interim analysis is any analysis intended to compare treatment arms for efficacy or safety, at any time prior to the formal completion of a trial.
Premature disclosure of clinical data prior to the finalization of a clinical trial risks jeopardizing the reliability of the trial data by affecting patient recruitment, biasing data collection and analysis or weakening confidence in the study conclusions. Disclosure of clinical information will be balanced with the need to retain the scientific integrity of clinical studies. Interim analyses will not be released if disclosure risks affecting the integrity of the study.
The decision to disclose clinical information within interim analyses will be taken case by case based on the following considerations:
|Situation involving an interim analysis:||Disclosure|
|An interim analysis that established clear superiority of the treatment for the condition(s) of use and that is used to stop the trial early||Favoured|
|An interim analysis of a clinical study that has been either completed or discontinued||Favoured|
|An ad hoc interim analysis of an ongoing trial that, if released, may impact the integrity of the study results and possibly weaken confidence in the conclusions drawn||Not favoured|
2.4 Individual patient records (individual patient listings and case report forms)
Clinical case report forms (e.g. ICH E3 16.3) are documents designed to record information on each trial subject as required by the clinical study protocol. Individual patient listings (e.g. ICH E3 16.2) include demographic data, individual efficacy response data, and listings of individual laboratory measurements by patient.
Collectively, these records represent a significant volume of a clinical study report. Due to a combination of structured and unstructured personal information, considerable de-identification is required before public release.
Due to this extensive requirement for de-identification, and the effects of these data modifications on overall data utility, individual patient records will not be released proactively as part of this initiative. Health Canada is considering other mechanisms through which individual patient records could be made available on request.
2.5 Implementation schedule for the proactive disclosure of clinical information in drug submissions and medical device applications
Health Canada intends to proactively release clinical information in drug submissions and medical device applications according to the following implementation stages, following the circumstances outlined in paragraph C.08.009.2 of the FDR and Section 43.12 (1) of the MDR.
|Stage||Proposed Phase-in||Scope of application types|
|1||Year 1||NDS-NAS + SNDS-c + Rx-switch|
|2||Year 2||All NDS + SNDS-c + Rx-switch|
|3||Year 3||All NDS, all SNDS & Class IV devices|
|4||Year 4||All NDS, SNDS, ANDS, SANDS + Class III & IV devices|
Implementation Step 1
In the first stage of implementation of proactive public release, Health Canada aims to publish the clinical information within drug submissions for:
- new active substances (NDS-NAS), representing submissions for drugs that are not variations of previously approved medicinal ingredients in Canada, i.e. “innovative” drugs;
- supplemental new drug submissions containing confirmatory trials (SNDS-c) following the issuance of a Notice of Compliance with conditions as agreed to in the Letter of Undertaking; and
- submissions to switch an authorized medicinal ingredient to non-prescription status (Rx-switch for full switch and partial switch submissions).
Implementation Step 2
In stage two, Health Canada intends on adding the proactive publication of clinical information within all new drug submissions (both NDS-NAS and those not categorized as new active substances).
Implementation Step 3
In stage three, Health Canada intends on adding the proactive publication of clinical information within all supplemental new drug submissions (SNDS) (e.g. submissions for new indications to a marketed product), and in-scope clinical information within Class IV medical device applications.
It is anticipated that the timing of stage three will align with the adoption of the IMDRF-TOC application structure for medical device applications, to permit the efficient publication of class III and IV clinical information.
Implementation Step 4
In stage four, Health Canada intends on adding the proactive publication of clinical information from abbreviated new drug submissions (ANDS; i.e. generic drug approvals), and from Class III medical device applications.
2.6 On-request publication of clinical information found in past drug submissions and medical device applications
Clinical information from past drug submissions and medical device applications (received by Health Canada prior to the coming into force of the regulations) may be requested through Health Canada’s clinical information portal. The information available for public release may be found in the following submission and application types:
- New Drug Submissions (NDS)
- Supplemental New Drug Submissions (SNDS)
- Abbreviated New Drug Submissions (ANDS)
- Supplemental Abbreviated New Drug Submissions (SANDS)
- Extraordinary Use New Drug Submissions (EUNDS)
- Supplemental Extraordinary Use New Drug Submissions (SEUNDS)
- Class III Medical Device Application
- Class III Medical Device Application Amendment
- Class IV Medical Device Application
- Class IV Medical Device Application Amendment
A request for clinical information from past submissions should be submitted using the online request form on Health Canada’s clinical information portal, as described in section 3 (Procedures).
The publication of clinical information under the Public Release of Clinical Information initiative proceeds through five distinct phases - initiation, submission, review, finalization, and publication.
Health Canada aims to upload a final redacted and de-identified clinical information package onto Health Canada’s clinical information portal within 60 days from initiation of the process. In the event that a request is received for clinical information that is not currently in an electronic format, additional time may be required for digitization of paper records.
3.1 Health Canada initiation of the publication of clinical information
Positive regulatory decisions
Publication of clinical trial information is initiated upon issuance of the qualifying regulatory decision (i.e. notice of compliance or medical device licence) on the submission / application; initiation triggers an email notification to the manufacturer, though manufacturers may start to prepare clinical information for publication prior to receiving the Health Canada notification.
The notification email identifies the drug submission or medical device application, and lists the documents Health Canada will publicly release (see appendices A, B, and C for a list of these documents). Health Canada requests that within 20 days the manufacturer submit the de-identified documents with proposed redaction(s). A redaction control sheet and anonymization report must also be submitted, as described below.
Negative regulatory decisions
In the event a drug submission is found to not comply with the FDR, Health Canada will initiate publication 31 days after the date of the notice, unless a Letter of Intent for Reconsideration has been received from the manufacturer.
In the event the manufacturer submits a Letter of Intent for Reconsideration, Health Canada will initiate publication upon completion of the reconsideration process, as described in the guidance “Reconsideration of Final Decisions Issued for Human Drug Submissions”. This is expected to require 70-140 days, depending on whether the request is referred for internal or external review.
In the event a medical device application is found to not comply with the MDR and the manufacturer submits a Letter of Intent to Appeal, Health Canada will initiate publication upon issuance of a decision of the appeal process, in accordance with the guidance “Management of Applications for Medical Device Licences and Investigational Testing Authorizations”.
In the case of a first-level appeal, should the manufacturer not submit the necessary information supporting the appeal, Health Canada will initiate publication 21 days after receipt of a manufacturer’s Letter of Intent to Appeal to the Bureau Director. In the case of a second-level appeal, Health Canada will initiate publication upon notification to the manufacturer of the Directorate’s decision on the appeal.
How to request clinical information from past submissions
Health Canada intends to publish clinical information from past submissions upon receipt of a request from the public.
Members of the public may request clinical information from past submissions through Health Canada’s clinical information portal with an electronic request form identifying the product name and the information requested (e.g. clinical study report, clinical overview, clinical summary).
Where possible, the requester should provide Health Canada with the submission/application number, study name, the name of the manufacturer, and the date of the regulatory decision (e.g. notice of compliance). This additional information is available within Health Canada’s Summary Basis of Decision, and Regulatory Decision Summary documents associated with the drug submission or medical device application.
Upon receipt of a request for clinical information, Health Canada will prioritize the request (see below), conduct an internal search for records, and publish the requested information on its clinical information portal.
Prioritization of requests
In the event requests for information exceed Health Canada’s administrative capacity, Health Canada will process requests for clinical information in priority sequence. Health Canada’s prioritization of requests will consider metrics that identify products and information with high health system impact. These considerations include prioritizing drugs or medical devices that are subject to ongoing queries by health system organizations, products that are abundantly used, and products that have demonstrated to be of high public interest.
3.2 Submission of annotated documents with proposed CBI redaction(s) and anonymization
Health Canada has described limited and specific circumstances, prescribed in regulations, where information found within the clinical component of a drug submission or medical device application may possess ongoing commercial value following the final regulatory decision. The specific categories of information that Health Canada will consider for redaction (with sufficient justification) are described in section 4 of this Guide.
The justification of certain redactions may require the manufacturer to draw on information within their internal corporate plans (e.g. future development of new indications based on secondary outcome data). Consequently, Health Canada requests that the manufacturer submit an annotated version of all clinical information in scope of publication with any and all proposed redactions highlighted. Any text the manufacturer proposes to redact must remain readable, and all proposed redactions should be recorded in the “Proposed redactions control sheet” alongside specific and detailed justification. Please refer to Appendix F for the control sheet template.
The annotated documents must also be de-identified in accordance with the process outlined in section 5 of this Guide. The process of data anonymization should be detailed in a separate Anonymization Report (see Appendix G for the Anonymization Report template).
Once the manufacturer has prepared the above documents, Health Canada requests that the documents be transmitted through the Common Electronic Submissions Gateway (CESG). Documents submitted via the CESG must follow the defined naming convention outlined in Appendix E.
Health Canada may return to the manufacturer on one additional occasion to seek additional justification. The final decision on what clinical information is publicly released rests with Health Canada.
Relying on previously-redacted information
With appropriate certification, the manufacturer may submit to Health Canada final redacted documents that were previously accepted by the EMA. Upon receipt of a Health Canada notification to prepare annotated documents for public release, in the case that this clinical information was previously released by the EMA under policy 0070, the manufacturer can choose this alternative pathway.
Manufacturers must submit final redacted documents using the CESG, as above.
Health Canada requests that manufacturers submit their certification using the template certification form found in Appendix H. Submission of this form attests that the clinical information in scope of Health Canada’s Public Release of Clinical Information is identical to the clinical information published under policy 0070.
In circumstances where only a component of the information requested for release by Health Canada was previously redacted for the EMA, manufacturers may resubmit the same information with certification, and only redact the outstanding components for Health Canada.
3.3 Health Canada review of annotated documents
Health Canada will review the manufacturer’s justifications for each proposed redaction within the annotated documents. All proposed redactions will be assessed against the exceptions permitted under the regulations (see section 4). Following review, proposed redactions will be accepted or rejected prior to finalization of the clinical information for public release.
Proposed redactions may be rejected for the following reasons:
- When the manufacturer fails to adequately demonstrate how the information was not used to support the conditions of use or purpose for the drug or device, as set out in the submission or application;
- When the manufacturer fails to adequately justify how the proposed information describes a test, method, or assay that is used exclusively by the manufacturer;
- When the manufacturer fails to demonstrate that the proposed information is out of scope of the regulations;
- When the proposed redaction pertains to information already in the public domain.
Health Canada will inform the manufacturer of any proposed redactions that the Department rejects. Manufacturers will be given one additional opportunity to further justify a redaction following Health Canada’s review.
As outlined in section 5, Health Canada requests the manufacturer to anonymize the clinical information using a risk-based anonymization process. Health Canada’s review will reject the transformation of any data that is not accompanied by adequate justification. Health Canada retains final decision on what information is publicly released.
3.4 Finalization of redacted documents
Following Health Canada’s review, the manufacturer must submit a final version of the redacted documents, according to Health Canada instruction:
All accepted proposed redactions must be converted into non-readable text; redacted text should not be machine-readable or searchable.
All proposed data transformations for the purposes of anonymization should be finalized; a revised anonymization report which excludes any personal information will be prepared to accompany the final anonymized clinical documents (see Section 5 for more information on the requirements for the anonymization report).
The final redacted documents should be named in accordance with the naming conventions identified in Appendix E, and submitted to Health Canada via the CESG.
3.5 Publication of final redacted documents
4. Requirements for the redaction of Confidential Business Information
Two categories of clinical information will remain subject to the FDA definition of CBI. With justification by the manufacturer, Health Canada may protect the following from public release:
- Clinical information that was not used by the manufacturer in the submission, application or supplement to support the proposed conditions of use for the new drug or the purpose for which the new drug is recommended; or
- Clinical information that describes tests, methods or assays used exclusively by the manufacturer.
1) As per C.08.009.2(2)(a) of the FDR, clinical information submitted by the manufacturer but that did not support the proposed conditions of use for the drug, or the purpose for which the drug is recommended, does not cease to be confidential business information following Health Canada’s regulatory decision.
Similarly, as per s43.12(2)(a) of the MDR, clinical information submitted by the manufacturer but that did not support the features of the device that permit it to be used for the medical conditions, purposes and uses for which it is manufactured, sold, or represented, does not cease to be confidential business information following Health Canada’s regulatory decision.
As an example, a manufacturer may be using secondary or exploratory outcome measure data described in the clinical information to support future trials to gain approval for a new indication of use. Release of this information could provide a competitor with insight about the drug’s future uses.
Clinical study reports, overviews, and summaries may contain data and discussion about secondary or exploratory end points that do not support the conditions of use or purpose of the product for which the submission or application seeks market authorization. In the rare instance where this information may form a component of an on-going development programme for new claims, given adequate justification Health Canada will protect this information from public release.
2) As per C.08.009.2(2)(b) of the FDR and s43.12(2)(b) of the MDR, clinical information in respect of tests, methods or assays that are used exclusively by the manufacturer do not cease to be CBI following Health Canada’s regulatory decision.
As an example, a manufacturer may develop novel modifications to a bioassay that is then used to collect clinical data. In certain instances, such modifications may rely on considerable effort and investment by the manufacturer and may be used for other ongoing studies or other routine use. Such modifications may be considered to be exclusively used by the manufacturer.
Clinical study reports, overviews, and summaries may include details, specifications, and validation information on assays and/or test methods developed exclusively by the submission sponsor or another third party and used exclusively by the submission sponsor. In the event that these methodological details have not been published in the public domain, and with adequate justification, Health Canada will protect this information from public release.
5. Anonymization of personal information
5.1 Principles of protecting personal information
The federal Privacy Act defines "personal information" as information about an identifiable individual that is recorded in any form; specific and non-exhaustive examples are then listed. Clinical information contains information that falls under this definition of personal information.
The federal court has adopted the “serious possibility” test to determine when information is about an identifiable individual (Gordon v. Canada (Health), 2008 FC 258). Clinical information must be adequately de-identified prior to public disclosure to avoid the serious possibility of identifying individual clinical trial patients; this requires the application of an objective, systematic, and documented process of anonymization.
In order to maximize the release of analytically-valuable information and to retain the most utility of the published clinical information, the anonymization of clinical information should be guided by the following principles:
1 - All transformation of data should be conducted for the sole purpose of preventing the disclosure of personal information;
2 - All data transformations should be accompanied by robust justification, and be applied to limited variables that risk re-identification, not to broad sections of clinical information;
3 - Data transformation should favour methods that retain analytical value, e.g. generalization, randomization and offsetting, as opposed to redaction.
5.2 Anonymization process:
Many anonymization frameworks currently exist and are publicly available. Health Canada encourages a 3 step process adapted from the 2016 Information and Privacy Commissioner of Ontario de-identification guidance. The process of anonymization should broadly follow the following three stages:
Step 1: Classify the variables
Step 2: Measure the data risk
Step 3: De-identify the data
By adopting an anonymization process that follows these broad steps, the risk of disclosing personal information can be reliably reduced in an objective and documented manner. An anonymization approach which includes risk measurement and accurate reference population selection provides further benefits by maximizing data utility while inherently adjusting for variable sensitivities of certain study populations.
Step 1: Classify the variables
Directly-identifying and indirectly-identifying variables must be classified prior to processing the clinical information for anonymization.
Directly-identifying variables are commonly described as information that meets the test of being:
A - Replicable, in the sense that the variable is unlikely to frequently vary over time;
B - Distinguishable, in the sense that individual patients may have distinct recognizable values; and
C - Knowable, in the sense that someone knows the variable associated with a certain individual.
Directly-identifying variables can be either uniquely identifying (e.g. a patient’s social insurance number), or not uniquely identifying (e.g. date of birth). Generally, variables classified as directly-identifying are not considered analytically useful (e.g. patient initials), with limited exceptions (e.g. subject identification numbers). The disclosure of directly-identifying variables poses a serious risk of re-identifying an individual.
Indirectly-identifying variables are other identifying variables that fall within the definition of ‘personal information’ within Canada’s Privacy Act. In order for an indirectly-identifying variable to require anonymization, its disclosure must pose a serious risk of re-identifying an individual, when combined with other available information (e.g. demographic data). Indirectly-identifying variables are analytically useful, and therefore their anonymization must be carefully justified, in line with the guiding anonymization principle number 2.
Step 2: Measure the data risk
Once the variables have been classified, the data risk needs to be measured. This risk measurement provides justification for any data transformation that may follow. Variables which do not present a serious risk of re-identifying an individual are not considered personal information and should not be transformed.
The overall risk of re-identification associated with the disclosure of clinical data is the product of the risk inherent to the data and the risk associated with the context of the release. For the public release of clinical information (to the general public), the calculation of risk of re-identification needs to reflect this environment; in a public release environment, the context risk is unreducible, so the overall risk of re-identification is equivalent to the risk inherent to the data (as opposed to the release of information to a small and select group of individuals, which would constitute a lower context risk, and therefore a lower risk of re-identification).
Measurement of data risk for directly-identifying variables
Directly-identifying variables possess a serious risk of identifying a trial participant, and should be assumed to carry a 100% risk of re-identification (risk=1.0); invariably these variables require anonymization in order to sufficiently reduce the risk of trial participant re-identification.
Measurement of data risk for indirectly-identifying variables
The risk of re-identification for indirectly-identifying variables associated with a patient needs to be calculated on a patient level. One straightforward method of calculating the risk of re-identification for indirectly-identifying variables is to measure the cell size.
Cell size is defined as the number of patients with the same indirectly-identifying variable values. Adopting a risk threshold of risk=0.09 equates to a target cell size of 11 patients. Once indirectly-identifying variables in need of anonymization are identified, the data for the corresponding patients should be de-identified in order to achieve a cell size of 11.
The selection of the estimated population size determines the group size and the amount of anonymization (i.e. data transformation) that is required to be applied. The reference population can be informed from patients in the single trial in question (smallest population), all patients in similar trials by a specific study sponsor, all patients in similar trials (i.e. by disease or therapeutic intervention category), or all patients in a geographic area (largest population).
A sampling fraction from the reference population can be used to achieve an estimate of the population size. In keeping with the first and second guiding principle, risk of re-identification should be informed not only by the number of individuals in a single study, but rather by the number that reflects real-world risk.
Health Canada encourages adopting a 9% re-identification risk threshold (risk=0.09). This aligns with the risk threshold cited in the EMA Policy 0070 External Guidance and is in agreement with other public data disclosure risk thresholds. While a qualitative approach to risk measurement can be taken, a quantitative approach has the advantage of being based on empirical measurement and consequently is more precise, less subjective, and typically retains more data utility.
Step 3: De-identify the data
The process of anonymization, including the method of de-identification applied, can have a detrimental effect on the utility of the data. Data that is preserved retains the greatest utility. Consequently, it is advisable to not transform (de-identify) variables that do not contribute to the risk of re-identification, and to adopt methods that have the lowest impact on data utility.
De-identification of directly-identifying variables
Directly-identifying variables may be anonymized through the process of redaction, pseudonymization, or randomization. While directly-identifying variables that do not possess analytical utility may be redacted, other directly identifying variables which possess analytical utility, such as subject IDs, may be pseudonymized (re-coded) in order to preserve the capacity to link clinical trial participant data throughout the study records.
Directly identifying variables that may be redacted include:
|signatures||health plan beneficiary numbers|
|job titles/positions||batch/serial numbers|
De-identification of indirectly-identifying variables
Health Canada encourages the generalization of indirectly identifying variables. These variables may include: city, state/province, zip/postal code, demographic data (race, gender, etc.), medical history, serious adverse events, dates, height, weight, and BMI. Note that the country should remain unmodified.
In certain circumstances, following generalization, the variable should be resynthesized to avoid the appearance of anonymization. The subsequent resynthesis is expected to achieve further risk reduction due to inability to identify leaked identifiers.
Documenting the anonymization process and governance
The process of anonymization should be thoroughly documented to provide the necessary audit trail. Health Canada requests that the manufacturer submit a completed Anonymization Report (template provided in Appendix G) with the submission of all anonymized clinical information.
Appendix A: Structure and content of ICH CTD/eCTD M2.5, M2.7 and M5
|2.5 Clinical Overview||Not CBI||Yes|
|2.5.1 Product Development Rationale||Not CBI||Yes|
|2.5.2 Overview of Biopharmaceutics||Not CBI||Yes|
|2.5.3 Overview of Clinical Pharmacology||Not CBI||Yes|
|2.5.4 Overview of Efficacy||Not CBI||Yes|
|2.5.5 Overview of Safety||Not CBI||Yes|
|2.5.6 Benefits of Risks Conclusions||Not CBI||Yes|
|2.5.7 Literature References||Not CBI||Yes|
|2.7.1 Summary of biopharmaceutics and associated analytical methods||Not CBI||Yes|
|126.96.36.199 Background and Overview||Not CBI||Yes|
|188.8.131.52 Summary of Results of Individual Studies||Not CBI||Yes|
|184.108.40.206 Comparison and Analyses of Results Across Studies||Not CBI||Yes|
|220.127.116.11 Appendix||Not CBI||Yes|
|2.7.2 Summary of clinical pharmacology studies||Not CBI||Yes|
|18.104.22.168 Background and Overview||Not CBI||Yes|
|22.214.171.124 Summary of Results of Individual Studies||Not CBI||Yes|
|126.96.36.199 Comparison and Analysis of Results Across Studies||Not CBI||Yes|
|188.8.131.52 Special Studies||Not CBI||Yes|
|184.108.40.206 Appendix||Not CBI||Yes|
|2.7.3 Summary of clinical efficacy||Not CBI||Yes|
|220.127.116.11 Background and Overview of Clinical Efficacy||Not CBI||Yes|
|18.104.22.168 Summary of Results of Individual Studies||Not CBI||Yes|
|22.214.171.124 Comparison and Analyses of Results Across Studies||Not CBI||Yes|
|126.96.36.199 Analysis of Clinical Information Relevant to Dosing Recommendations||Not CBI||Yes|
|188.8.131.52 Persistence of Efficacy and/or Tolerability Effects||Not CBI||Yes|
|184.108.40.206 Appendix||Not CBI||Yes|
|2.7.4 Summary of clinical safety||Not CBI||Yes|
|220.127.116.11 Exposure to the Drug||Not CBI||Yes|
|18.104.22.168.1 Overall Safety Evaluation Plan and Narratives of Safety Studies||Not CBI||Yes|
|22.214.171.124.2 Overall Extent of Exposure||Not CBI||Yes|
|126.96.36.199.3 Demographic and Other Characteristics of Study Population||Not CBI||Yes|
|188.8.131.52 Adverse Events||Not CBI||Yes|
|184.108.40.206.1 Analysis of Adverse Events||Not CBI||Yes|
|220.127.116.11.2 Narratives||Not CBI||Yes|
|18.104.22.168 Clinical Laboratory Evaluations||Not CBI||Yes|
|22.214.171.124 Vital Signs, Physical Findings, and Other Observations Related to Safety||Not CBI||Yes|
|126.96.36.199 Safety in Special Groups and Situations||Not CBI||Yes|
|188.8.131.52.1 Intrinsic Factors||Not CBI||Yes|
|184.108.40.206.2 Extrinsic Factors||Not CBI||Yes|
|220.127.116.11.3 Drug Interactions||Not CBI||Yes|
|18.104.22.168.4 Use in Pregnancy and Lactation||Not CBI||Yes|
|22.214.171.124.5 Overdose||Not CBI||Yes|
|126.96.36.199.6 Drug Abuse||Not CBI||Yes|
|188.8.131.52.7 Withdrawal and Rebound||Not CBI||Yes|
|184.108.40.206.8 Effects on Ability to Drive or Operate Machinery or Impairment of Mental Ability||Not CBI||Yes|
|220.127.116.11 Post-marketing Data||Not CBI||Yes|
|18.104.22.168 Appendix||Not CBI||Yes|
|2.7.5 Literature References||Not CBI||No|
|2.7.6 Synopses of Individual Studies||Not CBI||No|
|5.1 Table of Contents of Module||Not CBI||No|
|5.2 Tabular Listing of All Clinical Studies||Not CBI||No|
|22.214.171.124 Bioavailability (BA) Study Reports||Not CBI||Yes|
|126.96.36.199 Comparative BA and Bioequivalence (BE) Study Reports||Not CBI||Yes|
|188.8.131.52 In vitro- In vivo Correlation Study Reports||Not CBI||No|
|184.108.40.206 Reports of Bioanalytical and Analytical Methods for Human Studies||Not CBI||No|
|220.127.116.11 Plasma Protein Binding Study Reports||Not CBI||Yes|
|18.104.22.168 Reports of Hepatic Metabolism and Drug Interaction Studies||Not CBI||Yes|
|22.214.171.124 Reports of Studies Using Other Human Biomaterials||Not CBI||Yes|
|126.96.36.199 Healthy Subject PK and Initial Tolerability Study Reports||Not CBI||Yes|
|188.8.131.52 Patient PK and Initial Tolerability Study Reports||Not CBI||Yes|
|184.108.40.206 Intrinsic Factor PK Study Reports||Not CBI||Yes|
|220.127.116.11 Extrinsic Factor PK Study Reports||Not CBI||Yes|
|18.104.22.168 Population PK Study Reports||Not CBI||Yes|
|22.214.171.124 Healthy Subject PD and PK/PD Study Reports||Not CBI||Yes|
|126.96.36.199 Patient PD and PK/PD Study Reports||Not CBI||Yes|
|188.8.131.52 Study Reports of Controlled Clinical Pertinent to the Claimed Indication||Not CBI||Yes|
|184.108.40.206 Study Reports of Uncontrolled Clinical Studies||Not CBI||Yes|
|220.127.116.11 Reports of Analysis of Data from More than One Study||Not CBI||Yes|
|18.104.22.168 Other Study Reports||Not CBI||Yes|
|5.3.6 Reports of post-marketing experience||Not CBI||No|
|5.3.7 Case report forms and individual patient listings, when submitted||Not CBI||No|
|5.4 Literature References||Not CBI||No|
*For a description of the submission elements please refer to the ICH M4E(R2) Guideline
Appendix B: Structure and Content of ICH CTD/eCTD Module 5.3 Clinical Study Reports
|Section||Description||CBI||Public Proactive Release|
|1||Title page||Not CBI||Yes|
|3||Table of contents for the individual clinical study report||Not CBI||Yes|
|4||List of abbreviations and definition of terms||Not CBI||Yes|
|5.1||Independent ethics committee (ICE) or institutional review board (IRB)||Not CBI||Yes|
|5.2||Ethical conduct of the study||Not CBI||Yes|
|5.3||Patient information and consent||Not CBI||Yes|
|6||Investigators and study administrative structure||Not CBI||Yes|
|8||Study objectives||Not CBI||Yes|
|9||Investigational plan||Not CBI||Yes|
|9.1||Overall study design and plan – description||Not CBI||Yes|
|9.2||Discussion of study design, including the choice of control groups||Not CBI||Yes|
|9.3||Selection of study population|
|9.3.1||Inclusion Criteria||Not CBI||Yes|
|9.3.2||Exclusion Criteria||Not CBI||Yes|
|9.3.3||Removal of Patients from Therapy or Assessment||Not CBI||Yes|
|9.4.1||Treatments Administered||Not CBI||Yes|
|9.4.2||Identity of Investigational Product(s)||Not CBI||Yes|
|9.4.3||Method of Assigning Patients to Treatment Groups||Not CBI||Yes|
|9.4.4||Selection of Doses in the Study||Not CBI||Yes|
|9.4.5||Selection and Timing of Dose for each Patient||Not CBI||Yes|
|9.4.7||Prior and Concomitant Therapy||Not CBI||Yes|
|9.4.8||Treatment Compliance||Not CBI||Yes|
|9.5||Efficacy and safety variables|
|9.5.1||Efficacy and Safety Measurements Assessed and Flow Chart||Not CBI||Yes|
|9.5.2||Appropriateness of Measurements||Not CBI||Yes|
|9.5.3||Primary Efficacy Variable(s)||Not CBI||Yes|
|9.5.4||Drug Concentration Measurements||Not CBI||Yes|
|9.6||Data quality assurance||Not CBI||Yes|
|9.7||Statistical methods planned in the protocol and determination of sample size|
|9.7.1||Statistical and Analytical Plans||Not CBI||Yes|
|9.7.2||Determination of Sample Size||Not CBI||Yes|
|9.8||Changes in the conduct of the study or planned analyses||Not CBI||Yes|
|10.1||10.1 disposition of patients||Not CBI||Yes|
|10.2||Protocol deviations||Not CBI||Yes|
|11.1||Data sets analysed||Not CBI||Yes|
|11.2||Demographic and other baseline characteristics||Not CBI||Yes|
|11.3||Measurements of treatment compliance||Not CBI||Yes|
|11.4||Efficacy results and tabulations of individual patient data||Not CBI||Yes|
|11.4.1||Analysis of Efficacy||Not CBI||Yes|
|11.4.2||Statistical/Analytical Issues||Not CBI||Yes|
|22.214.171.124||Adjustments for Covariates Selection||Not CBI||Yes|
|126.96.36.199||Handling of Dropouts or Missing Data||Not CBI||Yes|
|188.8.131.52||Interim Analyses and Data Monitoring||Not CBI||Yes|
|184.108.40.206||Multicentre Studies||Not CBI||Yes|
|220.127.116.11||Multiple Comparison/Multiplicity||Not CBI||Yes|
|18.104.22.168||Use of an "Efficacy Subset" of Patients||Not CBI||Yes|
|22.214.171.124||Active-Control Studies Intended to Show||Not CBI||Yes|
|126.96.36.199||Examination of Subgroups||Not CBI||Yes|
|11.4.3||Tabulation of Individual Response Data||Not CBI||Yes|
|11.4.4||Drug Dose, Drug Concentration, and Relationships to Response||Not CBI||Yes|
|11.4.5||Drug-Drug and Drug-Disease Interactions||Not CBI||Yes|
|11.4.6||By-Patient Displays||Not CBI||Yes|
|11.4.7||Efficacy Conclusions||Not CBI||Yes|
|12.1||Extent of exposure||Not CBI||Yes|
|12.2||Adverse events (AES)||Not CBI||Yes|
|12.2.1||Brief Summary of Adverse Events||Not CBI||Yes|
|12.2.2||Display of Adverse Events||Not CBI||Yes|
|12.2.3||Analysis of Adverse Events||Not CBI||Yes|
|12.2.4||Listing of Adverse Events by Patient||Not CBI||Yes|
|12.3||Deaths, other serious adverse events, and other significant adverse events||Not CBI||Yes|
|12.3.1||Listing of Deaths, other Serious Adverse Events and Other Significant Adverse Events||Not CBI||Yes|
|188.8.131.52||Other Serious Adverse Events||Not CBI||Yes|
|184.108.40.206||Other Significant Adverse Events||Not CBI||Yes|
|12.3.2||Narratives of Deaths, Other Serious Adverse Events and Certain Other Significant Adverse||Not CBI||Yes|
|12.3.3||Analysis and Discussion of Deaths, Other Serious Adverse Events and Other Significant Adverse Events||Not CBI||Yes|
|12.4||Clinical laboratory evaluation||Not CBI||Yes|
|12.4.1||Listing of Individual Laboratory Measurements by Patient (16.2.8) and Each Abnormal Laboratory Value (14.3.4)||Not CBI||Yes|
|12.4.2||Evaluation of Each Laboratory Parameter||Not CBI||Yes|
|220.127.116.11||Laboratory Values Over Time||Not CBI||Yes|
|18.104.22.168||Individual Patient Changes||Not CBI||Yes|
|22.214.171.124||Individual Clinically Significant Abnormalities||Not CBI||Yes|
|12.5||Vital signs, physical findings and other observations related to safety||Not CBI||Yes|
|12.6||Safety conclusions||Not CBI||Yes|
|13||Discussion and overall conclusions||Not CBI||Yes|
|14||Tables, figures and graphs referred to but not included in the text|
|14.1||Demographic data||Not CBI||Yes|
|14.2||Efficacy data summary figures and tables||Not CBI||Yes|
|14.3||Safety data summary figures and tables||Not CBI||Yes|
|14.3.1||Displays of Adverse Events||Not CBI||Yes|
|14.3.2||Listings of Deaths, Other Serious and Significant Adverse Events||Not CBI||Yes|
|14.3.3||Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events||Not CBI||Yes|
|14.3.4||Abnormal Laboratory Value Listing (Each Patient)||Not CBI||Yes|
|15||Reference list||Not CBI||Yes|
|16.1.1||Protocol and protocol amendments||Not CBI||Yes|
|16.1.2||Sample case report form (unique pages only)||Not CBI||Yes|
|16.1.3||List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms||Not CBI||No|
|16.1.4||List and description of investigators and other important participants in the study, including brief (1 page) CVs or equivalent summaries of training and experience relevant to the performance of the clinical study||Not CBI||No|
|16.1.5||Signatures of principal or coordinating investigator(s) or sponsor’s responsible medical officer, depending on the regulatory authority's requirement||Not CBI||No|
|16.1.6||Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used 28 Structure and Content of Clinical Study Reports||Not CBI||No|
|16.1.7||Randomisation scheme and codes (patient identification and treatment assigned)||Not CBI||No|
|16.1.8||Audit certificates (if available) (see Annex IVa and IVb of the guideline)||Not CBI||No|
|16.1.9||Documentation of statistical methods||Not CBI||Yes|
|16.1.10||Documentation of inter-laboratory standardisation methods and quality assurance procedures if used||Not CBI||No|
|16.1.11||Publications based on the study||Not CBI||No|
|16.1.12||Important publications referenced in the report||Not CBI||No|
|16.2||Patient data listings|
|16.2.1||Discontinued patients||Not CBI||No|
|16.2.2||Protocol deviations||Not CBI||No|
|16.2.3||Patients excluded from the efficacy analysis||Not CBI||No|
|16.2.4||Demographic data||Not CBI||No|
|16.2.5||Compliance and/or drug concentration data (if available)||Not CBI||No|
|16.2.6||Individual efficacy response data||Not CBI||No|
|16.2.7||Adverse event listings (each patient)||Not CBI||No|
|16.2.8||Listing of individual laboratory measurements by patient, when required by regulatory authorities No||Not CBI||No|
|16.3||Case report forms|
|16.3.1||CRFs for deaths, other serious adverse events and withdrawals for AE||Not CBI||No|
|16.3.2||Other CRFs submitted||Not CBI||No|
|16.4||Individual patient data listings (us archival listings)||Not CBI||No|
Appendix C: Structure and content of Section 4 of IMDRF ToC medical device application
|Section||Description||CBI||Public Proactive Release|
|4.1 - Chapter Table of Contents||Not CBI||No|
|4.2 - Overall Clinical Evidence Summary||A brief summary of the available clinical evidence being presented in support of the submission||Not CBI||Yes|
|4.2.1 Clinical Evaluation Report||An objective critical evaluation of all of the clinical data submitted in relation to the device.||Not CBI||Yes|
|4.2.2 Device Specific Clinical Trials|
|126.96.36.199||Trial description, protocol number, date of initiation||Not CBI||Yes|
|188.8.131.52.2||Clinical trial report||Not CBI||Yes|
|184.108.40.206.3||Clinical trial data||Not CBI||Yes|
|4.2.3||Clinical literature review and other reasonable known information||Not CBI||Yes|
|4.3 - IRB Approved Informed Consent Forms||US regional information not submitted to Health Canada||NA||NA|
|4.4 - Investigators Sites – IRB Contact Information||US regional information not submitted to Health Canada||NA||NA|
|4.5 - Other Clinical
|220.127.116.11||Summaries of specific studies||Not CBI||Yes|
|18.104.22.168||Full test report for specific studies||Not CBI||Yes|
Appendix D: Process flow chart
|PRCI Process step(s):||1 – Commence PRCI process:||2 – Product sponsor provides data package for PRCI:||3 – Health Canada internal review||4 – Sponsor review of PRCI package (if required):||5 – Publication of records in scope of PRCI:|
|Positive regulatory decision:
36(1)(a) or (b)
|Process starts on day of decision||
|Negative regulatory decision:
|Process delayed for 30 days for sponsor reconsideration(s) or appeal. Trigger of reconsideration or appeal process would delay process an additional 70-140 days.|
|Negative Decision||Day 0 + 30||Day 31-50||Day 51-65||Day 66-80||Up to 90 days total|
|Time forecasts:||(pos) = 0 days
(neg) = +30 days
|+20 days||+15 days||+15 days (if required)||+10 days|
Appendix E: Document naming convention for submissions through the CESG
Anonymized clinical information with proposed redactions and accompanying redaction justification tables and anonymization reports should be submitted via the CESG.
The file format in which documents must be submitted is PDF format.
The file naming convention for all documents with proposed redactions should follow the original file naming convention used in the original submission with the addition of “-PR” as a suffix. It is assumed that the original file naming convention was chosen in accordance with Health Canada’s Guidance Document: Preparation of Drug Regulatory Activities in the Electronic Common Technical Document Format.
“-PR” = proposed redaction
E.g. clinical-overview-PR.pdf, summary-clin-safety-PR.pdf, study-XXXXXX-PR.pdf
Once redactions are finalized, Health Canada will apply the “-RED” suffix, to the final anonymized documents prior to publication.
“-RED” = final redaction
E.g. clinical-overview-RED.pdf, summary-clin-safety-RED.pdf, study-XXXXXX-RED.pdf
Appendix F: Proposed redaction control sheet
|Document Name||Page Number(s)||Text proposed for redaction||Qualifying exception for regulations||Not clinical information||Detailed justification of proposed redaction||Health Canada’s response to proposed redaction||Health Canada’s rationale|
|E.g. exceptions: C.08.009.2 (2)(a) or C.08.009.2 (2)(b)||E.g. chemistry, manufacturing information||Rejected /
Partially Accepted / Accepted
Appendix G: Anonymisation report template
*Note: two versions of the anonymization report will be generated. The first submitted version must include detailed information on the anonymization methodology. Each data transformation must be identified and a rationale provided. Upon acceptance of the anonymization approach, Health Canada will remove any information that presents a risk of disclosing personal information within the anonymization report.
Submission control number:
Applicant/ Market Authorization Holder:
1. Anonymization methodology
- Describe the approach taken, the risk threshold used and the rationale for the chosen approach.
2. Identification of data variables (direct and indirect identifiers) and measurement of re-identification risk
- Classify the variables considered personal information into directly-identifying and indirectly-identifying categories.
- State and justify the reasons for describing information as personal information.
- State and justify the reference population used.
- Discuss the measured data risk associated with individual trial subjects found to be at risk of re-identification and how the data was transformed to reduce the risk.
- State the measured risk following the process of anonymization.
3. Data utility considerations
- State the efforts made to maximize the utility of the anonymized information.
Appendix H: Certification letter with table of previously redacted information
Drug Product Name:
I certify that the following information and data listed and provided in this submission is complete, accurate and correctly represents the redacted and anonymized information and material provided to the European Medicines Agency under policy 070 and the Canadian submission to which it refers.
Health Canada submission control number:
- Module 2:
- Section 2.5 (pages xxx to xxx)
- Section 2.7 (pages xxx to xxx)
- Module 5
- Clinical Study Name 1 (pages xxx to xxx)
- Clinical Study Name 2 (pages xxx to xxx)
I certify that the following information has not been redacted and anonymized, and is unique to the Canadian submission:
- Module 2:
- Section 2.5 (pages xxx to xxx)
- Section 2.7 (pages xxx to xxx)
- Module 5
- Clinical Study Name 1 (pages xxx to xxx)
- Clinical Study Name 2 (pages xxx to xxx)
OR Not applicable
Signature of the responsible officer of the company certifying the accuracy of this document.
It is prohibits a person against knowingly making false or misleading statements or providing false or misleading information to the Minister in connection with any matter under the Act concerning a therapeutic product. (Food and Drugs Acts, 21.6)
Appendix I: Terms and conditions of use
“Manufacturer” means the current owner of a Drug Identification Number, or person or business holding a medical device licence.
"Clinical Information” means clinical trial information as per the meaning in C.08.009.1 (1) of the FDR, or information on a clinical study or investigational testing as per the meaning in s43.11 of the MDR, which includes clinical overviews, clinical summaries, clinical study reports, clinical study report appendices 16.1.1, 16.1.2, and 16.1.9, for drugs and the detailed information of all clinical studies and investigational testing that provided evidence of biological safety for medical devices.
"You” means you personally and, as applicable, if you are accessing and using the information on behalf of your employer, that employer, and its affiliates.
2. Representations and Warranties
You represent and warrant:
a. the accuracy of the information you submitted to create your User Account in order to obtain Clinical Information.
b. that if you are accessing Clinical Information on behalf of your employer, that you have the full legal authority to bind your employer.
c. that your access to Clinical Information is solely for non-commercial purposes.
3. Use of Clinical Information
3.2 You agree to only use, reproduce or communicate reasonable parts of Clinical Information (a) for non-commercial purposes, and not to (b) use the information to support a marketing authorisation application anywhere in the world, (c) sell or trade the information to another person, or (c) otherwise make any unfair commercial use of Clinical Information.
3.4 When reproducing Clinical Information, you agree to not misrepresent the source of the Clinical Information and to acknowledge that the source of the information is the Manufacturer and not use the information in a way that suggests that the Manufacturer endorses your use of the Clinical Information for any other purpose other than non-commercial purposes.
3.5 You agree not to seek to re-identify the trial subjects or other individuals from Clinical Information and to report to Health Canada if Clinical Information includes any inadvertent disclosure of personal information.
3.7 You agree that you will not share your username, password or other account details with a third party or otherwise provide a third party with access to your User account.
3.8 You agree to notify Health Canada of any possible unauthorized uses of your User Account.
3.9 You agree to provide Health Canada with all the information that Health Canada may request from time to time to confirm your identity, role or activities, in accordance with the conditions, including deadlines, set out in any such request.
5. Limitation of liability and Indemnification
Without prejudice to any of the obligations of the Manufacturer under the laws of Canada, Clinical Information is provided on an “AS IS” and “AS AVAILABLE” basis. By accessing and using Clinical Information, you agree that said access and use is entirely at your own risk. Health Canada and the Manufacturer exclude all representations, warranties, obligations and liabilities in relation to Clinical Information as made accessible to you to the maximum extent permitted by law. Neither Health Canada nor the Manufacturer are liable for any errors or omissions in Clinical Information as made accessible to you and shall not be liable for any loss, injury or damage of any kind caused by its use.
8. Governing Laws and Jurisdiction
Report a problem or mistake on this page
- Date modified: